How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
- PMID: 22845482
- PMCID: PMC3492839
- DOI: 10.1586/erm.12.46
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
Abstract
Cancers are complex multifactorial diseases. For centuries, conventional organ-based classification system (i.e., breast cancer, lung cancer, colon cancer, colorectal cancer, prostate cancer, lymphoma, leukemia, and so on) has been utilized. Recently, molecular diagnostics has become an essential component in clinical decision-making. However, tumor evolution and behavior cannot accurately be predicted, despite numerous research studies reporting promising tumor biomarkers. To advance molecular diagnostics, a better understanding of intratumor and intertumor heterogeneity is essential. Tumor cells interact with the extracellular matrix and host non-neoplastic cells in the tumor microenvironment, which is influenced by genomic variation, hormones, and dietary, lifestyle and environmental exposures, implicated by molecular pathological epidemiology. Essentially, each tumor possesses its own unique characteristics in terms of molecular make-up, tumor microenvironment and interactomes within and between neoplastic and host cells. Starting from the unique tumor concept and paradigm, we can better classify tumors by molecular methods, and move closer toward personalized cancer medicine and prevention.
Conflict of interest statement
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Figures
References
-
- Baudhuin LM, Donato LJ, Uphoff TS. How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Expert Rev. Mol. Diagn. 2012;12(1):25–37. - PubMed
-
- Roukos DH. Novel clinico–genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 2010;10(1):33–48. - PubMed
-
- Metodiev MV. Biomarkers research in Europe: focus on personalized medicine. Expert Rev. Mol. Diagn. 2011;11(7):689–690. - PubMed
-
- Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod. Pathol. 2008;21(Suppl. 2):S23–S30. - PubMed
-
- Gulley ML, Braziel RM, Halling KC, et al. Clinical laboratory reports in molecular pathology. Arch. Pathol. Lab. Med. 2007;131(6):852–863. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources